Immunic (IMUX) EBIT (2013 - 2026)

Immunic has reported EBIT for 14 years, with the latest figure at -$33.2 million in Q1 2026.

• Quarterly EBIT fell 23.9% year-over-year to -$33.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$109.6 million (down 8.56% YoY) and the FY2025 annual result came in at -$103.2 million, down 5.28% from the prior year.
• EBIT declined to -$33.2 million in Q1 2026 per IMUX's latest filing, from -$23.3 million in the prior quarter.
• Over five years, EBIT peaked at -$20.1 million in Q3 2022 and troughed at -$57.3 million in Q4 2022.
• A 5-year average of -$26.7 million and a median of -$25.0 million in 2023 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2023: EBIT tumbled 163.92% in 2022, then soared 59.21% in 2023.
• Over 5 years, EBIT stood at -$57.3 million in 2022, then jumped by 59.21% to -$23.4 million in 2023, then decreased by 9.62% to -$25.6 million in 2024, then gained by 8.99% to -$23.3 million in 2025, then slumped by 42.47% to -$33.2 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$33.2 million, -$23.3 million, and -$26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.